LIQUIDITY (Details) - USD ($) $ in Thousands, shares in Millions |
1 Months Ended | 2 Months Ended | 3 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|
Jul. 23, 2019 |
Jan. 31, 2019 |
Apr. 30, 2019 |
Aug. 31, 2019 |
Sep. 30, 2019 |
Sep. 30, 2018 |
Jun. 30, 2019 |
Jun. 30, 2018 |
|
| LIQUIDITY | ||||||||
| Net loss | $ (5,080) | $ (3,365) | $ 30,400 | |||||
| Net cash used in operating activities | (8,929) | (1,432) | 15,300 | |||||
| Accumulated deficit | (131,983) | (126,903) | ||||||
| Cash, cash equivalents and restricted cash | 25,215 | $ 401 | 11,573 | $ 1,646 | ||||
| Liabilities | 5,954 | $ 10,500 | ||||||
| Cash proceeds from equity offering | $ 25,000 | $ 113,600 | $ 22,600 | |||||
| Number of shares issued | 69.0 | 82.9 | ||||||
| Licensing obligations | $ 3,600 | |||||||
| Spending on research and development | 10,500 | |||||||
| Spending on compensation, benefits, rent and public company costs for auditing and professional fees | $ 8,900 | |||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of research and development expenses and other clinical program costs. No definition available.
|
| X | ||||||||||
- Definition Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. No definition available.
|
| X | ||||||||||
- Definition The compensation expense recognized during the period pertaining to the deferred compensation arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cumulative amount of the reporting entity's undistributed earnings or deficit. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|